Centralized pain and spinal cord stimulator trials: why screening and expectations matter now (2026-09-29)

This article from CMS Pain Management & Rehab, dated 2026-09-29, explains how features of centralized (nociplastic) pain can influence how a spinal cord stimulator (SCS) trial is interpreted, and outlines preparation and discussion points for a careful pain-clinic evaluation. SCS trial stimulation is used in some programs to help determine the potential fit of neuromodulation for chronic pain, but short-term pain ratings during a trial have limited ability to predict post-implant outcomes, so expectations are best framed broadly and cautiously [6 (opens in a new tab), 11 (opens in a new tab)]. A 2026 peer‑reviewed study examined how centralized pain features relate to outcomes after SCS trialing, highlighting the growing interest in how pain phenotypes may shape decision-making [3 (opens in a new tab)].

What is centralized (nociplastic) pain, and why might it matter for neuromodulation?

Centralized, or nociplastic, pain refers to pain arising from altered nociceptive processing without clear ongoing tissue damage or nerve injury to fully explain the symptoms. Common features can include widespread or migratory pain, sensory hypersensitivity, fatigue, sleep disturbance, and symptom flares that are not tightly linked to a single anatomical lesion [1 (opens in a new tab)]. The term overlaps with ideas of central sensitization and highlights that pain is shaped by nervous-system processing as well as by tissue inputs [2 (opens in a new tab)]. These characteristics can complicate one-to-one matching between a localized spinal target and a person’s everyday pain experience, which is relevant when considering trial stimulation that aims to modulate specific neural pathways [1 (opens in a new tab), 2 (opens in a new tab)].

How clinics screen for centralized features without overinterpreting a single score

Pain clinics may use a combination of history, examination, and patient-reported tools to characterize pain mechanisms and contributing factors [6 (opens in a new tab)]. The Central Sensitization Inventory (CSI) is one validated questionnaire that screens for symptom clusters often seen with central sensitization; it can help flag patterns to discuss, but it is not a diagnostic test by itself and should be interpreted in context [8 (opens in a new tab), 2 (opens in a new tab)]. Broader pain phenotyping frameworks emphasize that individuals can have mixtures of nociceptive, neuropathic, and nociplastic features that vary over time, which argues for individualized assessment rather than assuming a single mechanism dominates [2 (opens in a new tab)]. Small pilot work has suggested that dynamic symptom phenotypes may relate to the degree of pain reduction observed with SCS in some people, though such exploratory findings require cautious interpretation and further study [12 (opens in a new tab)].

What an SCS trial can and cannot tell you

Consensus guidance describes SCS trial stimulation as a structured, time-limited assessment that may inform whether a permanent implant is considered, within a comprehensive, multi-domain evaluation of goals and risks [6 (opens in a new tab)]. Programs vary in their criteria for interpreting a trial response, and many consider more than a single pain-intensity number, such as changes in function, sleep, and quality of life alongside safety and tolerance of paresthesia or paresthesia-free settings [6 (opens in a new tab)]. However, recent research indicates that short-term pain metrics collected during trialing have limited predictive utility for longer-term post-implant outcomes, so trial findings should be interpreted as one piece of a broader picture rather than a prediction of later results [11 (opens in a new tab)].

Technologies and programming approaches also vary across systems, including open-loop methods and closed-loop strategies that attempt to adjust stimulation based on measured spinal signals; such differences can influence the trial experience and follow-up if a device is pursued [9 (opens in a new tab)]. Experimental imaging work further suggests that SCS effects may involve changes across spinal and brain networks rather than a single pathway, which can help explain why responses differ among individuals and across time [4 (opens in a new tab)].

Interpreting a trial when centralized features are part of the pain picture

When prominent nociplastic features are present, day-to-day variability, widespread sensitivity, sleep disturbance, stress reactivity, and symptom flares can make short snapshots of pain more volatile [1 (opens in a new tab), 2 (opens in a new tab)]. That volatility can blur simple pass–fail thresholds that rely only on brief pain ratings [11 (opens in a new tab)]. In addition, if pain is not confined to one neuroanatomical territory, perceived coverage or relief during a targeted spinal trial may feel uneven, even if certain pain components respond during testing [1 (opens in a new tab), 2 (opens in a new tab)]. Evidence syntheses and clinic guidelines therefore encourage multi-domain, individualized evaluation and careful discussion of expectations rather than viewing a trial as a definitive predictor of long-term outcomes [6 (opens in a new tab), 11 (opens in a new tab)].

A 2026 study examined how measures of centralized pain relate to outcomes after SCS trials, reflecting ongoing efforts to understand whether such features moderate or mediate response patterns; this research direction is active, and the field continues to refine how to integrate phenotyping into patient-centered decisions [3 (opens in a new tab)]. Early pilot work has also explored how dynamic symptom phenotypes correlate with SCS-induced changes, adding to, but not resolving, the picture [12 (opens in a new tab)]. Overall, centralized features can shape interpretation, but they do not, by themselves, determine a specific outcome, and uncertainty remains [3 (opens in a new tab), 11 (opens in a new tab)].

  • Pain intensity across multiple times of day rather than a single daily snapshot, noting the context of activities, sleep, and stressors [6 (opens in a new tab)].
  • Function and activity tolerance using concrete anchors, such as walking time, standing time, or task completion, recorded consistently across trial days [6 (opens in a new tab)].
  • Sleep quality and awakenings, since disturbed sleep can amplify next-day pain reporting and function [1 (opens in a new tab)].
  • Flares or hypersensitivity triggers, including whether thresholds for touch or movement feel different from baseline, without drawing conclusions from isolated moments [1 (opens in a new tab), 2 (opens in a new tab)].
  • Any clinician-directed changes in medications, their timing, and non-pharmacologic strategies used during the trial; do not make medication changes without the prescribing clinician [6 (opens in a new tab)].
  • Adverse sensations, skin changes, or unusual neurologic symptoms during the trial, with prompt reporting to the clinical team according to the program’s instructions [6 (opens in a new tab)].

Preparing for a responsible SCS evaluation at CMS Pain Management & Rehab

A careful evaluation considers the mechanism mix of your pain, prior responses to treatments, functional goals, and safety factors [6 (opens in a new tab)]. Many programs include psychological assessment and structured goal-setting because mood, coping style, and expectations can influence perceived benefit and day-to-day function [6 (opens in a new tab)]. Tools like the CSI may be used as screens to support a broader conversation, not to label or exclude someone by a single score [6 (opens in a new tab), 8 (opens in a new tab), 2 (opens in a new tab)]. Bringing organized notes on symptom patterns, sleep, activity limits, previous therapies, and your current medication list can help the clinical team align programming plans and outcome measures with what matters most to you, without implying a particular treatment pathway [6 (opens in a new tab)].

Questions to discuss with a pain clinic before considering an SCS trial

  1. How will my pain phenotype be assessed, and how will features like widespread sensitivity or sleep disturbance be factored into interpreting any trial results? [2 (opens in a new tab), 6 (opens in a new tab), 8 (opens in a new tab)].
  2. Which outcome domains beyond pain intensity will we track during the trial, such as function, sleep, or quality of life, and how will variability be handled? [6 (opens in a new tab)].
  3. What constitutes a meaningful change for me, and how will limited predictive value of short trial metrics be considered when discussing next steps? [11 (opens in a new tab)].
  4. How are psychological factors, expectations, and coping addressed as part of selection and follow-up, and what supportive services are available? [6 (opens in a new tab)].
  5. What programming approaches are available here, and how do open-loop and closed-loop methods differ in setup and follow-up demands? [9 (opens in a new tab)].
  6. How does the clinic monitor and communicate device-related safety notices and recalls over time if I proceed further? [10 (opens in a new tab)].
  7. What imaging or anatomical considerations would guide lead placement if appropriate, and how would any red-flag symptoms change the plan? New bowel or bladder dysfunction, saddle numbness, or rapidly progressive weakness require immediate emergency evaluation (call 911 or go to the nearest emergency department), not a routine clinic visit [7 (opens in a new tab), 6 (opens in a new tab)].
  8. If trial results are mixed or inconclusive, what are the options for further assessment, optimization, or alternative care pathways within a rehabilitation-first framework? [6 (opens in a new tab)].

Safety first: symptoms that require immediate emergency evaluation

New or worsening bowel or bladder dysfunction, saddle numbness, or rapidly progressive leg weakness can indicate a serious spinal condition and require immediate emergency evaluation rather than a routine clinic appointment. New fever with back pain, history of significant trauma, or suspected infection also warrant urgent assessment. If such symptoms appear, seek immediate emergency care (call 911 or go to the nearest emergency department) [7 (opens in a new tab)].

Uncertainty, evolving evidence, and how to set balanced expectations

Pain phenotyping is a developing area [2 (opens in a new tab)]. While tools and frameworks can help organize thinking about nociceptive, neuropathic, and nociplastic components, no single score or label provides a complete answer, and heterogeneity is the rule rather than the exception [2 (opens in a new tab)]. CSI scores help screen for symptom clusters but do not diagnose a mechanism or dictate a treatment outcome on their own [8 (opens in a new tab)]. SCS trial results contribute information but have limited power to forecast longer-term outcomes after implantation, so they are best interpreted alongside functional measures, safety considerations, and patient-defined goals within a shared decision-making process [11 (opens in a new tab), 6 (opens in a new tab)]. Programming approaches and device technologies continue to evolve, including closed-loop methods and spinal targets under investigation, and imaging studies are beginning to map network-level effects; these developments are areas of active study, and individual responses vary [9 (opens in a new tab), 5 (opens in a new tab), 4 (opens in a new tab)]. The 2026 analysis of centralized pain and SCS outcomes adds to the literature but does not resolve all uncertainties, reinforcing the importance of individualized assessment and cautious expectation-setting [3 (opens in a new tab)].

Frequently asked questions

If I have signs of centralized pain, does that mean an SCS trial will not be informative?

Centralized features do not, by themselves, determine a specific SCS trial outcome. Some exploratory work suggests symptom phenotypes may relate to response patterns, but short-term trial metrics have limited ability to predict longer-term results, and guidelines emphasize individualized selection and multi-domain evaluation [12 (opens in a new tab), 11 (opens in a new tab), 6 (opens in a new tab), 3 (opens in a new tab)].

What is the CSI, and does it decide whether I am a candidate for SCS?

The Central Sensitization Inventory (CSI) is a validated screening questionnaire for symptom clusters associated with central sensitization. It can help organize discussion but is not a diagnostic test and should not be used alone to make treatment decisions, including SCS candidacy [8 (opens in a new tab), 2 (opens in a new tab)].

How long is an SCS trial, and how do programs interpret the results?

Trial duration and interpretation criteria vary by program and payer. Many clinics consider multiple domains such as pain, function, and sleep quality. There is no universal threshold that predicts longer-term outcomes, and research shows that short-term trial pain scores have limited predictive utility [6 (opens in a new tab), 11 (opens in a new tab)].

Do I need new spine imaging before a potential SCS trial?

Work-up depends on your history and exam. Imaging may be part of procedural planning in some cases. New bowel or bladder dysfunction — seek immediate emergency care or call 911, saddle numbness — seek immediate emergency care or call 911, or rapidly progressive weakness are emergencies that require immediate evaluation. Imaging decisions are individualized and not governed by a single timeline across all spine regions [6 (opens in a new tab), 7 (opens in a new tab)].

Sources

When to Talk With a Clinician

For non-emergency questions, contact CMS Pain Management & Rehab to discuss your symptoms and care options with a qualified clinician. For emergency warning signs, call 911 or seek emergency care now rather than contacting the clinic.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Treatment options, risks, and eligibility vary; consult a qualified healthcare professional.

This article provides general information and is not an individual diagnosis or treatment recommendation. Ask your clinician how the information relates to your health. The accompanying stock photograph is illustrative.

Originally published Sep 29, 2026. Last updated Sep 29, 2026.